By Carrie Capili, Communications Specialist, Editor
The NCCN Foundation, which through private philanthropy and grants, advances the mission of the National Comprehensive Cancer Network® (NCCN®) to improve the quality and effectiveness of care for patients with cancer, has awarded grants to five young investigators from the NCCN Member Institutions dedicated to advancing and discovering new treatments for cancer. The awards are the first ever made by the NCCN Foundation through its newly formed Young Investigator Awards Program. Each of the funded research initiatives will focus on assessing or improving outcomes of cancer care and carry grants of $150,000 over a two-year period. Funding will begin August 1, 2011.
"Throughout its history, NCCN has taken a leadership role in developing standards of care for delivering state-of-the-art cancer treatment and measuring outcomes. These grants not only strengthen our overall program in this critical area, but they also contribute to nurturing the next generation of cancer researchers in this country. We are very proud that we are able to make these awards at a time when both of these issues, defining quality in cancer care and supporting science, are so important," said William McGivney, PhD, Chief Executive Officer of NCCN.
Congratulations to the 2011 NCCN Foundation Young Investigator Awardees:
The awardees responded to a Request for Proposal (RFP) issued by the NCCN Foundation to the 21 NCCN Member Institutions. All submissions were reviewed by a multidisciplinary panel of oncology experts, and the awardees were selected based on several key components, including scientific merit and study design.
"This is an important and exciting initiative for NCCN and its Foundation. We are very pleased to have received such a large number of excellent proposals. This allowed us to make these awards to a diverse group of top young researchers, addressing different cancer types and issues, all very much in the scope of the NCCN mission," said Paul F. Engstrom, MD, Senior Vice President for Extramural Research Programs, Fox Chase Cancer Center, a member of the review committee.
These awards were made possible via contributions from the following companies: Amgen Inc., Genentech, Inc., Millennium Pharmaceuticals, and Pfizer Oncology.The NCCN Foundation was initiated in 2010, with a key goal in the first year of raising funds for the development and distribution of the NCCN Guidelines for Patients™. Six of these guidelines for patients are now available with another 10 planned for the coming year. The NCCN Guidelines for Patients™ use the same treatment algorithms that are the hallmark of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™), but are translated into a more user-friendly format utilizing language for non-professional audiences. The first Young Investigator Awards represent another major programmatic initiative for the NCCN Foundation.